Ovarian Function Suppression in HR+ Premenopausal Advanced Breast Cancer ~ NOW December 18th, 2024 Social Media CoordinatorNov 26, 20241 min readNEW UPDATE! To register, email Trish Ferrier at trish.ferrier@tersera.com. TTL-P-1077 Speaker Program Invitation - ONS (04-2024)_T. Ferrier_12-18.pdfDownload PDF • 271KB
CAR-Therapy Adverse Reaction Identification and Management Considerations ~ Thursday, June 12th @ Davio's
NEW EVENT: Exploring the Role of NUBEQA (darolutamide) in mHSPC in Combination with Docetaxel and in nmCRPC PP-NUM-US-3389-1
Commentaires